Introducing epiLiver: A High-throughput Test for Early Detection of Hepatocellular Carcinoma
HKG Epitherapeutics and icddr,b present epiLiver, a novel DNA methylation-based test poised to transform early detection of hepatocellular carcinoma (HCC). This innovative test offers a new hope in improving survival rates for those affected by this prevalent cancer.
Recent Comments
Great work, is this very specific to HCC? Have you tested other caner types`?
Thank you for your kind words and for your interest in our work. This high-throughput test has been specifically developed for the early detection of Hepatocellular Carcinoma (HCC). To ensure its specificity to HCC, the assay underwent testing on individuals with 15 different non-HCC cancers (Fig. 5, 6 and 7 of the manuscript).